EU/3/19/1285

About

On 25 July 2019, orphan designation EU/3/19/1285 was granted by the European Commission to Incyte Biosciences Distribution B.V., the Netherlands, for parsaclisib for the treatment of marginal zone lymphoma.

Key facts

Active substance
Parsaclisib
Disease / condition
Treatment of marginal zone lymphoma
Date of first decision
25/07/2019
Outcome
Positive
EU designation number
EU/3/19/1285

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Incyte Biosciences Distribution B.V.
Paasheuvelweg 25
1105 BP Amsterdam
The Netherlands
Tel. +31 202 619 313
E-mail: globalmedinfo@incyte.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating